Baseline Mast Cell Distribution Across the Body
Mast cells sit ready in skin, gut, and vessels, normal threshold.
- Skin/Gut/Vessels: Tissue sites (placeholder distribution)
- Normal: Activation threshold (placeholder baseline)
- Not required: IgE pathway (non-allergic mechanism)
- 0: Symptom systems (placeholder baseline count)
Mast cells as tissue-resident sentinels
Placeholder: mast cells reside widely, poised but quiescent normally.
Normal activation threshold
Placeholder: everyday stimuli stay below the firing threshold.
Post-COVID Mast Cells Become Hyperreactive
Non-specific triggers like heat or stress now provoke activation.
- Non-IgE: Mechanism (no allergen cross-linking)
- Heat/Stress/Exercise: Trigger types (placeholder examples)
- Lowered: Threshold shift (placeholder direction)
- Post-COVID: Onset context (placeholder timing)
Non-allergic trigger pathways
Placeholder: viral aftermath sensitizes mast cells to ordinary stimuli.
Idiopathic hyperactivation
Placeholder: no specific allergen is identifiable in most cases.
Diffuse Mediator Release Across Organ Systems
Histamine and tryptase release simultaneously in several tissues.
- Histamine: Mediator 1 (placeholder mediator)
- Tryptase: Mediator 2 (placeholder mediator)
- Diffuse: Release pattern (multi-site, not local)
- Dose-linked: Trigger dependence (placeholder relation)
Widespread degranulation
Placeholder: mediators escape from mast cells across body regions.
Dose-dependent trigger response
Placeholder: higher trigger exposure yields more mediator release.
Symptoms Emerge Across Multiple Body Systems
Flushing, GI upset, tachycardia, and brain fog appear together.
- Flushing: Skin (placeholder symptom)
- Cramping/diarrhea: GI (placeholder symptom)
- Tachycardia: Cardiac (placeholder symptom)
- Brain fog: Neuro (placeholder symptom)
Wide symptom footprint
Placeholder: distribution of mast cells explains scattered symptoms.
Overlap with Long COVID picture
Placeholder: MCAS symptoms mirror many reported Long COVID complaints.
Blockade and Stabilization Reduce Mediator Burden
H1/H2 blockers and cromolyn sodium calm mast cell output.
- Antihistamine: H1 blocker (placeholder class)
- Antihistamine: H2 blocker (placeholder class)
- Cromolyn sodium: Stabilizer (placeholder mechanism)
- Reduced release: Combined effect (placeholder outcome)
Receptor blockade
Placeholder: H1/H2 blockers reduce downstream histamine effects.
Membrane stabilization
Placeholder: cromolyn limits degranulation at the source.
Placeholder: combined blockade and stabilization lowers symptom burden most.